Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Rituximab as an adjunctive treatment for schizophrenia spectrum disorder or obsessive-compulsive disorder: Two open-label pilot studies on treatment-resistant patients
Susanne Bejerot, Sofia Sigra Stein, Elisabet Welin Henriksson, et al.
Journal of Psychiatric Research (2022) Vol. 158, pp. 319-329
Open Access | Times Cited: 15

Showing 15 citing articles:

Is It Time for a Paradigm Shift in the Treatment of Schizophrenia? The Use of Inflammation-Reducing and Neuroprotective Drugs—A Review
A. Messina, Carmen Concerto, Alessandro Rodolico, et al.
Brain Sciences (2023) Vol. 13, Iss. 6, pp. 957-957
Open Access | Times Cited: 24
Circular reasoning concerning Red flags for predicting rituximab response in OCD
Susanne Bejerot, A. Hietala, Annika Söderbergh, et al.
Molecular Psychiatry (2025)
Open Access | Times Cited: 1
IUPHAR review: Drug Repurposing in Schizophrenia – An Updated Review of Clinical Trials
Jihan K. Zaki, Jakub Tomasik, Sabine Bahn
Pharmacological Research (2025), pp. 107633-107633
Open Access | Times Cited: 1
IUPHAR Review - Novel therapeutic targets for schizophrenia treatment: a translational perspective
Veronica Begni, Alessia Marchesin, Marco Andrea Riva
Pharmacological Research (2025), pp. 107690-107690
Open Access | Times Cited: 1
Commentary on: “IUPHAR review - Novel therapeutic targets for schizophrenia treatment: A translational perspective.”
Mats B. Humble, Daniel Eklund, Susanne Bejerot
Pharmacological Research (2025), pp. 107757-107757
Open Access
Response to: “Circular reasoning concerning red flags for predicting rituximab response in OCD”
Maike Gallwitz, Isa Lindqvist, Annica J. Rasmusson, et al.
Molecular Psychiatry (2025)
Open Access
Study protocol for a randomized controlled trial with rituximab for psychotic disorder in adults (RCT-Rits)
Susanne Bejerot, Daniel Eklund, Hugo Hesser, et al.
BMC Psychiatry (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 7
Three cases with chronic obsessive compulsive disorder report gains in wellbeing and function following rituximab treatment
Maike Gallwitz, Isa Lindqvist, Jan Mulder, et al.
Molecular Psychiatry (2024)
Open Access | Times Cited: 2
Immunomodulatory treatment may change functional and structural brain imaging in severe mental disorders
Per Thunberg, David Fresnais, Paul B. Hamilton, et al.
Brain Behavior & Immunity - Health (2024) Vol. 41, pp. 100864-100864
Open Access | Times Cited: 2
Microglia and Other Cellular Mediators of Immunological Dysfunction in Schizophrenia: A Narrative Synthesis of Clinical Findings
Khoa D. Nguyen, Andrea Amerio, Andrea Aguglia, et al.
Cells (2023) Vol. 12, Iss. 16, pp. 2099-2099
Open Access | Times Cited: 3
Obsessive-Compulsive Disorder during the COVID-19 Pandemic
Federica Fiaschè, Georgios D. Kotzalidis, Alessandro Alcibiade, et al.
Psychiatry International (2023) Vol. 4, Iss. 2, pp. 102-104
Open Access | Times Cited: 2
Three cases with chronic obsessive compulsive disorder report gains in wellbeing and function following rituximab treatment
Janet L. Cunningham, Maike Gallwitz, Isa Lindqvist, et al.
Research Square (Research Square) (2024)
Open Access
Obsessive-Compulsive Disorder
Hassan I. Osman
International Journal of Research Publications (2024) Vol. 50, Iss. 1
Open Access
Characterization and modulation of voltage-gated potassium channels in human lymphocytes in schizophrenia
Marta Iglesias‐Martínez‐Almeida, Ana Campos-Ríos, Luis Freiría-Martínez, et al.
Schizophrenia Research (2024) Vol. 270, pp. 260-272
Closed Access
Study protocol for A randomized controlled trial with Rituximab for Psychotic disorder in adults (RCT-Rits)
Susanne Bejerot, Daniel Eklund, Hugo Hesser, et al.
Research Square (Research Square) (2023)
Open Access
Page 1

Scroll to top